WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Moderator

Barbara Rath, MD, PhD

Co-founder and Chair
Vaccine Safety Initiative
USA/Germany
Research Director
University of Bourgogne Franche-Comte
Besançon, France

Disclosures

Barbara Rath, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; GlaxoSmithKline (Data and Safety Monitoring Board chair); Roche

Faculty

Paolo Bonanni, MD

Professor of Hygiene
School of Medicine
Director
Department of Health Sciences University of Florence
Florence, Italy

Disclosures

Paolo Bonanni, MD, has the following relevant financial relationships:
Consultant or advisor for: AstraZeneca Pharmaceuticals LP; CSL Seqirus; GlaxoSmithKline; Janssen Pharmaceuticals; Merck Sharp & Dohme; Moderna, Inc.; Pfizer, Inc.; Sanofi Pasteur
Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; CSL Seqirus; GlaxoSmithKline; Janssen Pharmaceuticals; Merck Sharp & Dohme; Moderna, Inc.; Pfizer, Inc.; Sanofi Pasteur
Research funding from: AstraZeneca Pharmaceuticals LP; CSL Seqirus; GlaxoSmithKline; Merck Sharp & Dohme; Pfizer, Inc.; Sanofi Pasteur

Federico Martinón-Torres, MD, PhD

Head of Pediatrics
Director
Translational Pediatrics and Infectious Diseases
Hospital Clínico Universitario de Santiago
Coordinator
Genetics Vaccines Infections and Pediatrics Research Group
Healthcare Research Institute of Santiago de Compostela
Santiago de Compostela, Spain

Disclosures

Federico Martinón-Torres, MD, PhD, has the following relevant financial relationships:
Consultant or advisor for: Biofabri; GlaxoSmithKline; Janssen Pharmaceuticals; MedImmune Inc.; Merck Sharp & Dohme; Moderna, Inc.; Novavax, Inc.; Pfizer, Inc.; Sanofi
Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; CSL Seqirus; GlaxoSmithKline; Merck Sharp & Dohme; Moderna, Inc.; Pfizer, Inc.; Sanofi Pasteur
Research funding from: GlaxoSmithKline; Merck Sharp & Dohme; Pfizer Inc.; Sanofi
Other: Principal investigator of clinical trials for: Abbott; AstraZeneca Pharmaceuticals LP; CSL Seqirus; Cubist Pharmaceuticals; GlaxoSmithKline; MedImmune Inc.; Merck Sharp & Dohme; Novavax, Inc.; Pfizer, Inc.; Roche; Regeneron Pharmaceuticals, Inc.; Sanofi Pasteur

Editors

Alessia Piazza, PhD

Medical Education Director, WebMD Global, LLC

Disclosures

Alessia Piazza, PhD, has no relevant financial relationships.

Diana Lucifero, PhD

Scientific Content Manager, WebMD Global, LLC

Disclosures

Diana Lucifero, PhD, has no relevant financial relationships.

Compliance Reviewer

Stephanie Corder, ND, RN, CHCP

Associate Director, Accreditation and Compliance

Disclosures

Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

From Medscape Education

The Road to Safety: Understanding the Common and Less Common Side Effects of COVID-19 and Other Vaccines

Authors: Barbara Rath, MD, PhD; Paolo Bonanni, MD; Federico Martinón-Torres, MD, PhDFaculty and Disclosures

processing....

Patient Handout

Posted: 02/27/2023

This educational activity is intended for an international audience of non-US primary care physicians (PCPs), infectious disease (ID) specialists, and pediatricians.

The goal of this activity is for learners to be better able to understand the common and less common adverse events (AEs) following vaccination against COVID-19 and other viral infections.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Definition of AEs following immunization
- Common AEs following vaccination
- Less common AEs following vaccination

Educational Impact Challenge

The goal of this activity is for learners to be better able to understand the common and less common AEs following vaccination against COVID-19 and other viral infections.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 7

Download Slides

Activity Transcript

PDF Downloads

Patient Handout

Transcript Downloads

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of WebMD Global, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been authorized by the European Medicines Agency for use in Europe, off-label uses of authorized products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Moderator

Barbara Rath, MD, PhD

Faculty

Paolo Bonanni, MD

Federico Martinón-Torres, MD, PhD